piflufolastat f-18
Generic: PIFLUFOLASTAT F-18·Brand: PYLARIFY, PYLARIFY TRUVU
piflufolastat f-18: developed by 2 companies · 1 FDA decision.
piflufolastat f-18 evidence translation
What we can confirm
1 FDA record
What it means
More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
What is verified about piflufolastat f-18, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy and in men with suspected recurrence based on elevated PSA levels
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (3)
| Company | Phase |
|---|---|
| Lantheus Holdings, Inc. (LNTH) PET imaging of PSMA-positive lesions in men with prostate ca… | Approved |
| PROGENICS PHARMACEUTICALS INC (PGNX) | Approved |
| PROGENICS PHARMACEUTICALS INC (PGNX) | Approved |
FDA Decisions1 records
Frequently asked questions
Who is developing piflufolastat f-18?
piflufolastat f-18 is being developed by Lantheus Holdings, Inc., PROGENICS PHARMACEUTICALS INC.
What is piflufolastat f-18's latest FDA decision?
The most recent tracked FDA decision for piflufolastat f-18 is Approval, dated May 26, 2021.